These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

769 related articles for article (PubMed ID: 34341985)

  • 21. Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
    Shragai T; Gatt M; Lavie N; Vaxman I; Tadmor T; Rouvio O; Zektser M; Horowitz N; Magen H; Ballan M; Suru C; Luttwak E; Levi S; Ziv-Baran T; Avivi I; Cohen YC
    Eur J Haematol; 2021 Feb; 106(2):184-195. PubMed ID: 33090552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.
    Palladini G; Milani P; Foli A; Obici L; Lavatelli F; Nuvolone M; Caccialanza R; Perlini S; Merlini G
    Haematologica; 2014 Apr; 99(4):743-50. PubMed ID: 24213149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
    Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
    Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis.
    Warsame R; LaPlant B; Kumar SK; Laumann K; Perez Burbano G; Buadi FK; Gertz MA; Kyle RA; Lacy MQ; Dingli D; Leung N; Hayman SR; Kapoor P; Hwa YL; Fonder A; Hobbs M; Gonsalves WI; Kourelis T; Lust J; Russell SJ; Zeldenrust S; Lin Y; Muchtar E; Go RS; Vincent Rajkumar S; Dispenzieri A
    Blood Cancer J; 2020 Jan; 10(1):4. PubMed ID: 31913261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
    Palladini G; Dispenzieri A; Gertz MA; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
    J Clin Oncol; 2012 Dec; 30(36):4541-9. PubMed ID: 23091105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016.
    Rutten KHG; Raymakers RAP; Hazenberg BPC; Nienhuis HLA; Vellenga E; Minnema MC
    Amyloid; 2018 Dec; 25(4):227-233. PubMed ID: 30513220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.
    Hegenbart U; Bochtler T; Benner A; Becker N; Kimmich C; Kristen AV; Beimler J; Hund E; Zorn M; Freiberger A; Gawlik M; Goldschmidt H; Hose D; Jauch A; Ho AD; Schönland SO
    Haematologica; 2017 Aug; 102(8):1424-1431. PubMed ID: 28522573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
    Minarik J; Pika T; Radocha J; Jungova A; Straub J; Jelinek T; Pour L; Pavlicek P; Mistrik M; Brozova L; Krhovska P; Machalkova K; Jindra P; Spicka I; Plonkova H; Stork M; Bacovsky J; Capkova L; Sykora M; Kessler P; Stejskal L; Heindorfer A; Ullrychova J; Skacel T; Maisnar V; Hajek R
    BMC Cancer; 2021 Jan; 21(1):73. PubMed ID: 33451293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.
    Kastritis E; Wechalekar AD; Dimopoulos MA; Merlini G; Hawkins PN; Perfetti V; Gillmore JD; Palladini G
    J Clin Oncol; 2010 Feb; 28(6):1031-7. PubMed ID: 20085941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.
    Cibeira MT; Oriol A; Lahuerta JJ; Mateos MV; de la Rubia J; Hernández MT; Granell M; Fernández de Larrea C; San Miguel JF; Bladé J;
    Br J Haematol; 2015 Sep; 170(6):804-13. PubMed ID: 25974382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.
    Sachchithanantham S; Berlanga O; Alvi A; Mahmood SA; Lachmann HJ; Gillmore JD; Hawkins PN; Harding S; Wechalekar AD
    Br J Haematol; 2017 Nov; 179(4):575-585. PubMed ID: 28990174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
    Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
    Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
    Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
    Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival Outcomes.
    Diaz-Pallares C; Lee H; Luider J; Duggan P; Neri P; Tay J; MacCulloch S; Bahlis NJ; Jimenez-Zepeda VH
    Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):394-399. PubMed ID: 32146104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
    Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
    Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).
    Huang B; Li J; Xu X; Zheng D; Zhou Z; Liu J
    Pathol Biol (Paris); 2015 Feb; 63(1):17-20. PubMed ID: 25455933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.
    Dinner S; Witteles W; Afghahi A; Witteles R; Arai S; Lafayette R; Schrier SL; Liedtke M
    Haematologica; 2013 Oct; 98(10):1593-9. PubMed ID: 23716538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.
    Palladini G; Russo P; Milani P; Foli A; Lavatelli F; Nuvolone M; Perlini S; Merlini G
    Haematologica; 2013 Mar; 98(3):433-6. PubMed ID: 22983583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclophosphamide + Thalidomide + Dexamethasone Versus Melphalan + Dexamethasone for the Treatment of Amyloid Light-chain Amyloidosis With Kidney Involvement: A Retrospective Study in Chinese Patients.
    Liu B; Wang Y; Bai M; Wang D; Zhao J; Zhang M; Sun S
    Clin Ther; 2019 Jun; 41(6):1186-1198. PubMed ID: 30718006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.